Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bellerophon Therapeutics, Inc. (BLPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4500+0.0100 (+0.69%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4400
Open1.4500
Bid1.4000 x 2200
Ask1.4700 x 1000
Day's Range1.4200 - 1.4800
52 Week Range0.6700 - 4.4900
Volume14,936
Avg. Volume40,954
Market Cap13.784M
Beta (5Y Monthly)-0.27
PE Ratio (TTM)N/A
EPS (TTM)-2.2640
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.50
  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

    WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022. “The Bellerophon team continues to advance our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstitial lun

  • GlobeNewswire

    Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

    WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American Thoracis Society (ATS) 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA. Presentation Details Session C103: It's not just about IPFPoster Title: A Phase 2 Trial of INOpulse in

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

    WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on the continued advancement of our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstit

Advertisement
Advertisement